Dosing Calculator The calculator below may help you to calculate the necessary values to infuse your adult patients with ULTOMIRIS® (ravulizumab) 100 mg/mL.
ULTOMIRIS® is now available as 300 mg/3 mL and 1,100 mg/11 mL concentrates for solution for infusion. This calculator is intended for use when administering doses of ULTOMIRIS® 100 mg/mL only.* For dosing information regarding ULTOMIRIS® 10 mg/mL (300 mg/30 mL), please see the full Summary of Product Characteristics.1
Drag the button across the slider bar in order to select your patient's body weight (kg). The body weight variable will automatically snap to the nearest recognised figure in line with the ULTOMIRIS® weight-based dosing.
With ULTOMIRIS® 100 mg/mL, there is an optimal vial mix (3 mL and 11 mL) for each patient weight cohort, ensuring there is no product wastage.1

In the absence of compatibility studies, ULTOMIRIS® 300 mg/30 mL concrete for solution for infusion must not be mixed with ULTOMIRIS® 300 mg/3 mL or 1,100 mg/11 mL concentrates for solution for infusion.1
ULTOMIRIS® SmPC
* ULTOMIRIS® must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological or renal, neuromuscular or neuroinflammatory disorders.1

† SOLIRIS® (eculizumab) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.2

‡ ULTOMIRIS® should only be diluted using sodium chloride 9 mg/mL (0.9 %) solution for injection.1

§ Patients must be vaccinated against meningococcal infection 2 weeks prior to initiating treatment, or must be vaccinated at the of initiation of treatment whilst receiving prophylactic treatment with appropriate antibiotics until 2 week after vaccination.1

Adverse Event Reporting

Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com
ULTOMIRIS® Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: September 2024. SOLIRIS® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: September 2024. advance I am a healthcare professional registered in the EU I am not a
healthcare professional